Do you want to read an article? Please log in or register.
Bevacizumab for diabetic macular oedema: one-year treatment outcomes from the Fight Retinal Blindness! Registry
Macular Diseases
Related content
RECOMMENDED
Macular Diseases
Changes in real-world treatment patterns for diabetic macular oedema from 2009-2019 and five-year outcomes: Data from the Fight Retinal Blindness! Registry
★ 1
Recommended by
Prof. Dr emer. Josef Flammer, Faculty Member
doi: 10.1111/ceo.13781.
COMMENTED
Macular Diseases
Initial observation or treatment for diabetic macular oedema with good visual acuity: two-year outcomes comparison in routine clinical practice: data from the Fight Retinal Blindness! Registry
★ 2
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
Acta Ophthalmol
Gabrielle PH, Nguyen V, Bhandari S, Mehta H, Viola F, Arnold J, Fraser-Bell S, Barthelmes D, Creuzot-Garcher C, Gillies M
doi: 10.1111/aos.14672
RECOMMENDED
Macular Diseases
Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry
★ 3
Recommended by
Prof. Dr Daniel Barthelmes, Faculty Member
★ 3
Recommended by
Prof. Dr Ke Yao, Faculty Member
Ophthalmology.
Bhandari S, Nguyen V, Fraser-Bell S, Mehta H, Viola F, Baudin F, Gabrielle PH, Creuzot-Garcher C, Gillies M, Barthelmes D
doi: 10.1016/j.ophtha.2019.11.018.
RECOMMENDED
Macular Diseases
Outcomes of cataract surgery in eyes with diabetic macular oedema: Data from the Fight Retinal Blindness! Registry
★ 1
Recommended by
Prof. Dr Daniel Barthelmes, Faculty Member
doi: 10.1111/ceo.13707.
Macular Diseases
Retinal vascular calibre changes after intravitreal bevacizumab or dexamethasone implant treatment for diabetic macular oedema
Br J Ophthalmol.
Wickremasinghe SS, Fraser-Bell S, Alessandrello E, Mehta H, Gillies MC, Lim LL
doi: 10.1136/bjophthalmol-
Macular Diseases
Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration: Data from the Fight Retinal Blindness! Registry
Ophthalmology.
Bhandari S, Nguyen V, Arnold J, Young S, Banerjee G, Gillies M, Barthelmes D
doi: 10.1016/j.ophtha.2019.10.006.
COMMENTED
Macular DiseasesRetinal Diseases
Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry
★ 1
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
Acta Ophthalmol
Gabrielle PH, Nguyen V, Creuzot-Garcher C, Miguel L, Alforja S, Sararols L, Casaroli-Marano RP, Zarranz-Ventura J, Gillies M, Arnold J, Barthelmes D
doi: 10.1111/aos.14893
RECOMMENDED
Macular Diseases
FIVE-YEAR INCIDENCE AND VISUAL ACUITY OUTCOMES FOR INTRAVITREAL THERAPY IN BILATERAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Fight Retinal Blindness! Project
★ 2
Recommended by
PD Dr Moreno Menghini, Faculty Member
doi: 10.1097/IAE.0000000000002798.
COMMENTED
Macular Diseases
Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study)
doi: 10.1016/j.ophtha.2020.03.021.